Radiopharm Theranostics Ltd has released a press release.
Prospectus
Filed with ASX ·
On 6ix: 6ix.com/news/prospectus-38
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
Earlier from Radiopharm Theranostics
- RAD completes A$35 M Placement and launches A$5 M SPP
- Trading Halt
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Radiopharm received approval for RAD 202 trial acceleration
- SPL: Research & Option Agreement with Radiopharm Theranostics
Later from Radiopharm Theranostics
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- RADX: Program and Financial Updates
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics